Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

The green light is also a milestone for Novartis because it marks the first approval in its renal disease pipeline, which includes three therapies for IgAN – Fabhalta, oral endothelin A receptor ...

Clazosentan – an intravenously-administered endothelin A receptor antagonist – is designed to prevent cerebral vasospasm in aSAH patients, a sudden narrowing of blood vessels that can occur in ...

G Camp, a startup incubation platform dedicated to bringing Taiwan's startups to the global stage, is leading eight exceptional Taiwanese startups to participate in Web Summit, Europe's largest and ...

Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a landmark strategic partnership with the UK Government. This partnership ...